Paragon 28, Inc. (FNA)
After hours:
| Previous close | 10.53 |
| Open | 10.33 |
| Bid | 8.67 x 1000 |
| Ask | 9.50 x 1000 |
| Day's range | 9.46 - 10.68 |
| 52-week range | 7.95 - 19.00 |
| Volume | |
| Avg. volume | 526,080 |
| Market cap | 787.608M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
- Business Wire
Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
ENGLEWOOD, Colo., May 08, 2024--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance.
- Business Wire
Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference
ENGLEWOOD, Colo., May 02, 2024--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright, Interim CFO, will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024, at 5:00 p.m. Pacific Time / 6:00 p.m. Mountain Time.
Simply Wall St.Paragon 28, Inc. (NYSE:FNA) has caught the attention of institutional investors who hold a sizeable 36% stake
Key Insights Institutions' substantial holdings in Paragon 28 implies that they have significant influence over the...
